S. Miller

发表

Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.

A. Mestrovic, N. Chng, S. Tyldesley, 2022, JAMA oncology.

Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial

A. Louie, D. Palma, S. Gaede, 2020, BMC Cancer.

Use of single- versus multiple-fraction palliative radiation therapy for bone metastases: population-based analysis of 16,898 courses in a Canadian province.

I. Olivotto, K. Beecham, R. Olson, 2014, International journal of radiation oncology, biology, physics.

Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial

A. Louie, D. Palma, S. Gaede, 2020, BMC Cancer.

Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.

Howard Pai, Ingrid Spadinger, Stacy Miller, 2009, International journal of radiation oncology, biology, physics.

141 Acute and Late Urinary Toxicity in 606 Prostate Brachytherapy Patients

M. Keyes, V. Moravan, T. Pickles, 2006 .

Incidence of second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy.

W. J. Morris, M. Keyes, S. Tyldesley, 2014, International journal of radiation oncology, biology, physics.

Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up.

W. J. Morris, I. Spadinger, M. Keyes, 2009, International journal of radiation oncology, biology, physics.

Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals.

W. J. Morris, I. Spadinger, M. Keyes, 2014, International journal of radiation oncology, biology, physics.

Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? A secondary analysis of the population-based phase II SABR-5 trial.

A. Mestrovic, N. Chng, S. Tyldesley, 2023, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Palliative radiotherapy fractionation schedules prescribed are dependent on the distance a patient travels to receive treatment.

I. Olivotto, R. Olson, Scott Emmons, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Radiation oncology and medical physicists quality assurance in British Columbia Cancer Agency Provincial Prostate Brachytherapy Program.

Howard Pai, William James Morris, Ingrid Spadinger, 2013, Brachytherapy.

Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up.

I. Spadinger, M. Keyes, V. Moravan, 2009, International journal of radiation oncology, biology, physics.